RINVOQ® ,
Upadacitinib
Do not use upadacitinib if you are pregnant or plan to become pregnant. Based on animal studies, upadacitinib may harm your unborn baby. You should use effective birth control (contraception) to avoid becoming pregnant during treatment with upadacitinib and for 4 weeks after your last dose.
Upadacitinib may pass into your breast milk. Do not breastfeed during treatment with RINVOQ and for 6 days after your last dose.
Common side effects may include headache, fatigue, acne, nausea, urinary tract infection, and elevated cholesterol
Taking upadacitinib may include risk of serious infections, blood clots, certain types of cancer, and may increase risk of death or major cardiovascular events. To see the full prescribing information for this medication, click here.